Table. Meta-regression of the Effectiveness of Testosterone Treatment on Various Study-Level Moderators.
| Characteristic | Estimate (SE) [95% CI] | NHST | |
|---|---|---|---|
| χ2 (df) | P Value | ||
| Baseline | |||
| Age, y | |||
| 40 | 0.223 (0.198) [−0.166 to 0.612] | 0.835 (1) | .36 |
| 60 | 0.393 (0.116) [0.165 to 0.621] | ||
| 80 | 0.562 (0.238) [0.096 to 1.029] | ||
| Testosterone status | |||
| Eugonadal | 0.208 (0.221) [−0.225 to 0.641] | 1.021 (1) | .31 |
| Hypogonadal | 0.475 (0.144) [0.192 to 0.758] | ||
| HIV infection | |||
| Yes | 0.276 (0.331) [−0.373 to 0.926] | 0.096 (1) | .76 |
| No | 0.386 (0.123) [0.144 to 0.627] | ||
| Symptom level | |||
| Severe | 0.385 (0.232) [−0.070 to 0.840] | 1.194 (2) | .55 |
| Mild | 0.277 (0.155) [−0.027 to 0.582] | ||
| Subclinical | 0.595 (0.247) [0.112 to 1.078] | ||
| Symptom variability, CV, % | |||
| 20 | 0.615 (0.180) [0.262 to 0.968] | 2.935 (1) | .09 |
| 50 | 0.439 (0.116) [0.211 to 0.667] | ||
| 100 | 0.146 (0.169) [−0.185 to 0.478] | ||
| Treatment | |||
| Treatment dosage, g/wk | |||
| 0.1 | 0.166 (0.137) [−0.103 to 0.434] | 5.298 (1) | .02 |
| 0.3 | 0.312 (0.108) [0.100 to 0.524] | ||
| 1.0 | 0.823 (0.224) [0.383 to 1.263] | ||
| Treatment duration, wk | |||
| 5 | 0.363 (0.141) [0.086 to 0.640] | 0.012 (1) | .91 |
| 20 | 0.370 (0.117) [0.142 to 0.599] | ||
| 100 | 0.408 (0.345) [−0.268 to 1.083] | ||
| Administration | |||
| Intramuscular | 0.243 (0.141) [−0.033 to 0.520] | 3.352 (2) | .19 |
| Oral | 0.851 (0.306) [0.252 to 1.450] | ||
| Transdermal | 0.430 (0.222) [−0.006 to 0.865] | ||
Abbreviations: CV, coefficient of variation; NHST, null hypothesis significance test.